A multi-center, randomized, 36-month, parallel group, non-inferiority, phase III study to compare the effectiveness of 500 mcg QD or alternate regimen of roflumilast (Daliresp) therapy versus 250 mg QD, 500 mg QD three times per week, or alternate regime

Project: Federal Funding Agencies

Project Details

StatusActive
Effective start/end date12/1/215/31/23